Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Medicine
Volume 2015 (2015), Article ID 369707, 4 pages
http://dx.doi.org/10.1155/2015/369707
Case Report

Markedly Elevated Carbamazepine-10,11-epoxide/Carbamazepine Ratio in a Fatal Carbamazepine Ingestion

1The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA
2Nationwide Children’s Hospital, Columbus, OH 43205, USA
3Central Ohio Poison Center, Columbus, OH 43205, USA
4Franklin County Coroner’s Office, Columbus, OH 43201, USA

Received 13 July 2015; Revised 14 September 2015; Accepted 16 September 2015

Academic Editor: Bruno Megarbane

Copyright © 2015 Jason L. Russell et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. A. Spiller, “Management of carbamazepine overdose,” Pediatric Emergency Care, vol. 17, no. 6, pp. 452–456, 2001. View at Publisher · View at Google Scholar · View at Scopus
  2. J. Tibballs, “Acute toxic reaction to carbamazepine: clinical effects and serum concentrations,” The Journal of Pediatrics, vol. 121, no. 2, pp. 295–299, 1992. View at Publisher · View at Google Scholar · View at Scopus
  3. A. J. Macnab, P. Birch, and J. Macready, “Carbamazepine poisoning in children,” Pediatric Emergency Care, vol. 9, no. 4, pp. 195–198, 1993. View at Publisher · View at Google Scholar · View at Scopus
  4. H. A. Spiller, E. P. Krenelok, and E. Cookson, “Carbamazepine overdose—a prospective study of serum levels and toxicity,” Clinical Toxicology, vol. 28, no. 4, pp. 445–458, 1990. View at Publisher · View at Google Scholar · View at Scopus
  5. T. Tomson, O. Almkvist, B. Y. Nilsson, J.-O. Svensson, and L. Bertilsson, “Carbamazepine-10,11-epoxide in epilepsy: a pilot study,” Archives of Neurology, vol. 47, no. 8, pp. 888–892, 1990. View at Publisher · View at Google Scholar · View at Scopus
  6. B. F. D. Bourgeois and N. Wad, “Individual and combined antiepileptic and neurotoxic activity of carbamazepine and carbamazepine-10,11-epoxide in mice,” Journal of Pharmacology and Experimental Therapeutics, vol. 231, no. 2, pp. 411–415, 1984. View at Google Scholar · View at Scopus
  7. B. J. Fitzgerald and A. J. Okos, “Elevation of carbamazepine-10,11-epoxide by quetiapine,” Pharmacotherapy, vol. 22, no. 11, pp. 1500–1503, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. E. L. So, K. H. Ruggles, G. D. Cascino, P. A. Ahmann, and K. W. Weatherford, “Seizure exacerbation and status epilepticus related to carbamazepine-10,11-epoxide,” Annals of Neurology, vol. 35, no. 6, pp. 743–746, 1994. View at Publisher · View at Google Scholar · View at Scopus
  9. H. K. L. Hundt, A. K. Aucamp, and F. O. Muller, “Pharmacokinetic aspects of carbamazepine and its two major metabolites in plasma during overdosage,” Human Toxicology, vol. 2, no. 4, pp. 607–614, 1983. View at Publisher · View at Google Scholar · View at Scopus
  10. G. de Groot, A. N. P. van Heijst, and R. A. A. Maes, “Charcoal hemoperfusion in the treatment of two cases of acute carbamazepine poisoning,” Journal of Toxicology: Clinical Toxicology, vol. 22, no. 4, pp. 349–362, 1984. View at Publisher · View at Google Scholar
  11. P. N. Patsalos, S. Krishna, A. A. Elyas, and P. T. Lascelles, “Carbamazepine and carbamazepine-10,11-epoxide pharmacokinetics in an overdose patient,” Human Toxicology, vol. 6, no. 3, pp. 241–244, 1987. View at Publisher · View at Google Scholar · View at Scopus
  12. L. Bertilsson and T. Tomson, “Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update,” Clinical Pharmacokinetics, vol. 11, no. 3, pp. 177–198, 1986. View at Publisher · View at Google Scholar · View at Scopus
  13. E. Mesdjian, E. Sérée, B. Charvet et al., “Metabolism of carbamazepine by CYP3A6: a model for in vitro drug interactions studies,” Life Sciences, vol. 64, no. 10, pp. 827–835, 1999. View at Publisher · View at Google Scholar · View at Scopus
  14. S. C. Nallani, T. A. Glauser, N. Hariparsad et al., “Dose-dependent induction of cytochrome P450 (CYP) 3A4 and activation of pregnane X receptor by topiramate,” Epilepsia, vol. 44, no. 12, pp. 1521–1528, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. A.-S. Eriksson and L. O. Boreus, “No increase in carbamazepine-10,11-epoxide during addition of lamotrigine treatment in children,” Therapeutic Drug Monitoring, vol. 19, no. 5, pp. 499–501, 1997. View at Publisher · View at Google Scholar · View at Scopus
  16. F. M. C. Besag, D. J. Berry, F. Pool, J.-E. Newbery, and B. Subel, “Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction?” Epilepsia, vol. 39, no. 2, pp. 183–187, 1998. View at Publisher · View at Google Scholar · View at Scopus
  17. M. J. Tutor-Crespo, J. Hermida, and J. C. Tutor, “Relative proportions of serum carbamazepine and its pharmacologically active 10, 11-epoxy derivative: effect of polytherapy and renal insufficiency,” Upsala Journal of Medical Sciences, vol. 113, no. 2, pp. 171–180, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. D. Mckillop, M. J. Wild, C. J. Butters, and C. Simcock, “Effects of propofol on human hepatic microsomal cytochrome P450 activities,” Xenobiotica, vol. 28, no. 9, pp. 845–853, 1998. View at Publisher · View at Google Scholar · View at Scopus
  19. I. Burianová and K. Bořecká, “Routine therapeutic monitoring of the active metabolite of carbamazepine: is it really necessary?” Clinical Biochemistry, vol. 48, no. 13-14, pp. 866–869, 2015. View at Publisher · View at Google Scholar
  20. J. L. Harder, M. Heung, A. M. Vilay, B. A. Mueller, and J. H. Segal, “Carbamazepine and the active epoxide metabolite are effectively cleared by hemodialysis followed by continuous venovenous hemodialysis in an acute overdose,” Hemodialysis International, vol. 15, no. 3, pp. 412–415, 2011. View at Publisher · View at Google Scholar · View at Scopus